Abstract
Antibody-dependent enhancement (ADE) is a mechanism by which the pathogenesis of certain viral infections is enhanced in the presence of sub-neutralizing or cross-reactive non-neutralizing antiviral antibodies. In vitro modelling of ADE has attributed enhanced pathogenesis to Fcγ receptor (FcγR)-mediated viral entry, rather than canonical viral receptor-mediated entry. However, the putative FcγR-dependent mechanisms of ADE overlap with the role of these receptors in mediating antiviral protection in various viral infections, necessitating a detailed understanding of how this diverse family of receptors functions in protection and pathogenesis. Here, we discuss the diversity of immune responses mediated upon FcγR engagement and review the available experimental evidence supporting the role of FcγRs in antiviral protection and pathogenesis through ADE. We explore FcγR engagement in the context of a range of different viral infections, including dengue virus and SARS-CoV, and consider ADE in the context of the ongoing SARS-CoV-2 pandemic.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / biosynthesis
-
Antibodies, Neutralizing / administration & dosage
-
Antibodies, Neutralizing / adverse effects
-
Antibodies, Neutralizing / biosynthesis
-
Antibodies, Viral / administration & dosage*
-
Antibodies, Viral / adverse effects
-
Antibodies, Viral / biosynthesis
-
Antibody-Dependent Enhancement / drug effects*
-
Betacoronavirus / drug effects*
-
Betacoronavirus / immunology
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology
-
Coronavirus Infections / virology
-
Dengue / drug therapy
-
Dengue / immunology
-
Dengue / virology
-
Dengue Virus / drug effects
-
Dengue Virus / immunology
-
Dengue Virus / pathogenicity
-
Gene Expression Regulation
-
Host-Pathogen Interactions / drug effects
-
Host-Pathogen Interactions / immunology
-
Humans
-
Leukocytes / drug effects*
-
Leukocytes / immunology
-
Leukocytes / virology
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / virology
-
Receptors, IgG / antagonists & inhibitors
-
Receptors, IgG / genetics
-
Receptors, IgG / immunology*
-
SARS-CoV-2
-
Severe Acute Respiratory Syndrome / drug therapy
-
Severe Acute Respiratory Syndrome / immunology
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / drug effects
-
Severe acute respiratory syndrome-related coronavirus / immunology
-
Severe acute respiratory syndrome-related coronavirus / pathogenicity
-
Signal Transduction
-
Virus Internalization / drug effects
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Receptors, IgG